The pharmaceutical industry stands at a critical juncture as AI promises to revolutionize drug development. But separating genuine innovation from AI hype requires understanding the complex interplay between computational power and biological expertise that defines successful implementation.
The pharmaceutical industry’s race for obesity treatments has turned into a legal battle as Pfizer sues to block Novo Nordisk’s competing $9 billion bid for Metsera. This represents a major escalation in the fight for next-generation weight loss drugs.
Nvidia announces major telecom partnerships for 6G development and a $1 billion Nokia investment. Meanwhile, Eli Lilly reveals it has manufactured “billions of doses” of its oral weight loss drug orforglipron ahead of expected FDA submission.
